IL128416A - Use of Clioquinol for the preparation of a pharmaceutical preparation for the treatment of Alzheimer's disease and pharmaceutical preparations containing it - Google Patents

Use of Clioquinol for the preparation of a pharmaceutical preparation for the treatment of Alzheimer's disease and pharmaceutical preparations containing it

Info

Publication number
IL128416A
IL128416A IL12841697A IL12841697A IL128416A IL 128416 A IL128416 A IL 128416A IL 12841697 A IL12841697 A IL 12841697A IL 12841697 A IL12841697 A IL 12841697A IL 128416 A IL128416 A IL 128416A
Authority
IL
Israel
Prior art keywords
clioquinol
pharmaceutical composition
disease
alzheimer
treatment
Prior art date
Application number
IL12841697A
Other languages
English (en)
Hebrew (he)
Other versions
IL128416A0 (en
Original Assignee
Gerolymatos P N Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerolymatos P N Sa filed Critical Gerolymatos P N Sa
Publication of IL128416A0 publication Critical patent/IL128416A0/xx
Publication of IL128416A publication Critical patent/IL128416A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
IL12841697A 1996-08-13 1997-08-08 Use of Clioquinol for the preparation of a pharmaceutical preparation for the treatment of Alzheimer's disease and pharmaceutical preparations containing it IL128416A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GR96100286 1996-08-13
PCT/IB1997/000983 WO1998006403A1 (en) 1996-08-13 1997-08-08 Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
IL128416A0 IL128416A0 (en) 2000-01-31
IL128416A true IL128416A (en) 2004-06-01

Family

ID=10942479

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12841697A IL128416A (en) 1996-08-13 1997-08-08 Use of Clioquinol for the preparation of a pharmaceutical preparation for the treatment of Alzheimer's disease and pharmaceutical preparations containing it

Country Status (25)

Country Link
US (1) US6001852A (pl)
EP (1) EP0959888B1 (pl)
JP (1) JP2000516606A (pl)
KR (1) KR100489969B1 (pl)
CN (1) CN1114407C (pl)
AT (1) ATE205086T1 (pl)
AU (1) AU720643B2 (pl)
BR (1) BR9711194A (pl)
CA (1) CA2264097C (pl)
CZ (2) CZ295118B6 (pl)
DE (1) DE69706566T2 (pl)
DK (1) DK0959888T3 (pl)
ES (1) ES2162319T3 (pl)
HU (1) HUP9903906A3 (pl)
IL (1) IL128416A (pl)
IS (1) IS1907B (pl)
NO (1) NO316768B1 (pl)
NZ (1) NZ334124A (pl)
PL (1) PL188838B1 (pl)
PT (1) PT959888E (pl)
RU (1) RU2193406C2 (pl)
SI (1) SI0959888T1 (pl)
SK (1) SK283117B6 (pl)
TR (1) TR199900293T2 (pl)
WO (1) WO1998006403A1 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045531B1 (en) 1997-03-11 2006-05-16 The General Hospital Corporation Composition comprising a metal chelator and a method of treating amyloidosis by administering the metal chelator
BR9814945A (pt) * 1997-08-21 2000-09-05 Gerolymatos P N Sa Utilização de fanquinona para o tratamento de doença de alzheimer, composição farmacêutica e kit
AU760140B2 (en) * 1997-10-24 2003-05-08 John P. Blass Nutritional supplement for cerebral metabolic insufficiencies
US5994323A (en) * 1997-12-31 1999-11-30 P.N. Gerolymatos S.A. Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
US20020025944A1 (en) * 2000-04-28 2002-02-28 Bush Ashley I. Use of clioquinol for the therapy of Alzheimer's disease
US20050112543A1 (en) * 1998-03-11 2005-05-26 The General Hospital Corporation Method of screening for drugs useful in treating Alzheimer's disease
US6323218B1 (en) * 1998-03-11 2001-11-27 The General Hospital Corporation Agents for use in the treatment of Alzheimer's disease
US6638711B1 (en) 1999-04-29 2003-10-28 The General Hospital Corporation Methods for identifying an agent that inhibits oxygen-dependent hydrogen peroxide formation activity but does not inhibit superoxide-dependent hydrogen peroxide formation
WO2000040244A1 (en) 1999-01-07 2000-07-13 P.N. Gerolymatos S.A. Use of phanquinone for the treatment or prevention of memory impairment
US6692234B2 (en) 1999-03-22 2004-02-17 Water Management Systems Pump system with vacuum source
EP1256582A1 (en) * 2000-02-09 2002-11-13 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
FR2818551B1 (fr) * 2000-12-22 2007-06-01 Claude Marc Pierre Hannoun Utilisation de chelateurs pour le traitement des maladies a prions
US6803379B2 (en) * 2002-06-04 2004-10-12 Jose A. Fernandez-Pol Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
AU2002950217A0 (en) * 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
EP1558585B1 (en) * 2002-10-04 2013-09-25 Prana Biotechnology Limited Neurologically-active compounds
US20080063599A1 (en) * 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US20070037848A1 (en) * 2003-04-03 2007-02-15 Masters Colin L Treatment of neurological conditions
MXPA06005743A (es) * 2003-11-19 2007-04-17 Acrux Dds Pty Ltd Metodo y composicion para el tratamiento o profilaxis de trastornos de amiloidosis.
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
CN102764279B (zh) * 2005-10-14 2015-04-01 全面技术公司 改变细胞功能的方法和组合物
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
PT1976877E (pt) * 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
BRPI0619249A2 (pt) * 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
BRPI0722382A2 (pt) * 2006-04-14 2012-06-05 Prana Biotechnology Ltd compostos úteis para o tratamento de cáncer
PT2046833E (pt) * 2006-07-14 2013-11-27 Genentech Inc Anticorpo humanizado contra amilóide beta
NZ574188A (en) * 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
RU2338542C1 (ru) * 2007-03-20 2008-11-20 Игорь Анатольевич Помыткин Применение воды с пониженным содержанием дейтерия для приготовления средств лечения нейродегенеративных заболеваний и улучшения когнитивной функции
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
EP2586795B1 (en) 2007-10-05 2018-05-16 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
ES2332687B1 (es) * 2008-03-13 2011-01-10 Proyecto De Biomedicina Cima, S.L. Nuevos usos de 4pba y sus sales farmaceuticamente aceptables.
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
FR2966827B1 (fr) 2010-10-27 2014-08-22 Kimonella Ventures Ltd Compose peptidique utile pour l'inhibition de la formation de plaques amyloides
WO2014163622A1 (en) * 2013-04-02 2014-10-09 Annji Pharmaceutical Co., Ltd. Multifunctional quinoline derivatives as anti-neurodegenerative agents
EP3135280B1 (en) 2014-04-24 2023-09-20 Omoidesouzou Co. Ltd. Tranilast for the treatment of cutaneous amyloidosis
KR20160057500A (ko) * 2014-11-05 2016-05-24 아카데미아 시니카 클리오퀴놀을 포함하는 자폐증 스펙트럼 장애의 치료용 약학적 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE393238C (de) * 1923-05-12 1924-03-31 Maschb Akt Ges H Flottmann & C Bohrhammer
US3174899A (en) * 1960-12-30 1965-03-23 Ciba Geigy Corp Composition for the management of post antibiotic enteritis
US3178343A (en) * 1962-11-27 1965-04-13 Ciba Geigy Corp Pharmaceutical compositions and method of using same
DE1617417A1 (de) * 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
RU2057531C1 (ru) * 1986-07-01 1996-04-10 Всероссийский научный центр по безопасности биологически активных веществ Средство для стимуляции обучения и памяти
DE3932338A1 (de) * 1989-09-28 1991-04-11 Nmi Naturwissenschaftl U Mediz Verfahren zur praeventiven therapie von morbus alzheimer
GB9010039D0 (en) * 1990-05-03 1990-06-27 Reckitt & Colmann Prod Ltd Medicament preparation
GB9108080D0 (en) * 1991-04-15 1991-06-05 Smithkline Beecham Plc Pharmaceutical composition
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
EP0613560B2 (en) * 1991-11-12 2006-06-21 Prana Biotechnology Ltd A method for assaying and treating alzheimer's disease
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
WO1995019178A1 (en) * 1994-01-13 1995-07-20 Research Foundation For Mental Hygiene, Inc. Methods and compositions for treatment and diagnosis of alzheimer disease and other disorders
AU6580494A (en) * 1994-05-11 1995-12-05 P.N. Gerolymatos S.A. Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture

Also Published As

Publication number Publication date
NZ334124A (en) 2000-10-27
CA2264097C (en) 2007-11-27
IS4972A (is) 1999-02-10
CZ48499A3 (cs) 1999-07-14
EP0959888B1 (en) 2001-09-05
HUP9903906A2 (hu) 2000-04-28
DE69706566D1 (de) 2001-10-11
IS1907B (is) 2003-12-16
BR9711194A (pt) 2000-01-11
PT959888E (pt) 2002-02-28
CN1230115A (zh) 1999-09-29
SK283117B6 (sk) 2003-02-04
CZ292411B6 (cs) 2003-09-17
NO990595L (no) 1999-04-12
KR20000029958A (ko) 2000-05-25
PL188838B1 (pl) 2005-04-29
HK1022437A1 (en) 2000-08-11
CZ295118B6 (cs) 2005-05-18
ES2162319T3 (es) 2001-12-16
WO1998006403A1 (en) 1998-02-19
TR199900293T2 (xx) 1999-06-21
RU2193406C2 (ru) 2002-11-27
IL128416A0 (en) 2000-01-31
AU720643B2 (en) 2000-06-08
NO316768B1 (no) 1999-04-12
SK17999A3 (en) 1999-09-10
ATE205086T1 (de) 2001-09-15
AU3632497A (en) 1998-03-06
HUP9903906A3 (en) 2001-01-29
US6001852A (en) 1999-12-14
CA2264097A1 (en) 1998-02-19
JP2000516606A (ja) 2000-12-12
CN1114407C (zh) 2003-07-16
SI0959888T1 (en) 2002-10-31
DK0959888T3 (da) 2001-11-05
NO990595D0 (no) 1999-02-09
KR100489969B1 (ko) 2005-05-17
EP0959888A1 (en) 1999-12-01
DE69706566T2 (de) 2002-07-11
PL331822A1 (en) 1999-08-02

Similar Documents

Publication Publication Date Title
AU720643B2 (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
EP1061923B1 (en) Metal chelators for use in the treatment of alzheimer's disease
US7029710B2 (en) Methods of isolation of amyloid inhibitory ingredients within Uncaria tomentosa
WO1998040071A9 (en) Identification of agents for use in the treatment of alzheimer's disease
US5994323A (en) Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
DE69805305T2 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
US20050112543A1 (en) Method of screening for drugs useful in treating Alzheimer's disease
US20060074104A1 (en) Use of clioquinol for the therapy of alzheimer's disease
WO2000004912A1 (en) Therapeutic agent for dementia, comprising ginseng extract
MXPA99001466A (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
Dodion et al. Phase I clinical and pharmacokinetic study of zeniplatin, a new platinum complex
Ueda et al. Mechanism of the protective effect of sodium malate on cisplatin-induced toxicity in mice
HK1022437B (en) Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
Rahayu et al. In vitro Identification of the Iron-Chelating Potential of Kwini Mango (Mangifera odorata Griff) Leaf Extract in Iron Overload Cases
CA2601285A1 (en) Agents for use in the treatment of amyloidosis
FR2818551A1 (fr) Utilisation de chelateurs pour le traitement des maladies a prions
Page et al. New Strategies in Stroke Treatment
安増哲生 Comparative Study of Cisplatin and Carboplatin on Pharmacokinetics, Nephrotoxicity and Effect on Renal Nuclear DNA Synthesis in Rats

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees